Who We Are

A recognized leader in the industry, Jim has built and led multiple discovery and development-focused CROs, with an emphasis on ADME and bioanalysis. He has held senior leadership roles at Tandem Laboratories, Charles River Laboratories, and Primedica, among others. Jim was a co-founder, President, and CEO of Agilux Laboratories—a premier CRO specializing in discovery and development services in ADME, oncology pharmacology, as well as discovery and GLP small and large molecule bioanalysis. Ultimately, Jim (with his leadership team) negotiated the sale of Agilux to Charles River Laboratories. Jim received his BS and MS degrees from the University of Maryland at College Park and his Ph.D. from the University of North Carolina at Chapel Hill.

Xin comes to Meadowhawk Biolabs with deep CRO industry experience and a demonstrated leadership track record. Xin was the Global Head of DMPK and Bioanalytical Services at WuXi Apptec overseeing the multi-site operation in China and the U.S. Xin was responsible for all aspects of the DMPK service, strategically and operationally, and managed the Sales and Marketing team. Prior to WuXi Apptec, Xin served in various CRO leadership roles at Agilux Laboratories, Tandem Laboratories, and Charles River Laboratories. Xin began his career as a Principal Scientist at Maxygen working on protein sciences. Xin received his Ph.D. degree from the University of Iowa and did his post-doctoral work at the Barnett Institute of Northeastern University.

With more than twenty-five years in business development roles, Mary Ann has a successful and proven track record for building successful sales territories in the CRO industry. She began her career as a Research Associate in Pharmacology at Bayer Pharmaceuticals and Centocor and served as a Study Director at Primedica. She has previously served in a variety of business development roles including Charles River Laboratories, Gene Logic Laboratories, Agilux Laboratories, and others. She will bring her enthusiasm and strong commitment to customer service to Meadowhawk Biolabs. Mary Ann received her BA in Biology from Quinnipiac College and MS in Human Anatomy from Hahnemann University.

Brian has Director-level experience within CROs in the areas of bioanalysis operations (both non-GLP and regulated), and IT. His strong knowledge base in both science and operations, combined with his passion for the power of IT, have enabled him to be a noteworthy contributor in conceptualizing, evaluating, and deploying efficient systems. He most recently worked at Charles River Laboratories, coordinating the operations of Agilux Laboratories, Primedica and Synta Pharmaceuticals, after they were acquired by CRL. Brian earned his BS in chemistry from West Virginia University.

Jessica has held senior financial positions of progressively increasing responsibiliy, including Senior Finance Director and Controller, at several venture/equity funded start-ups and high growth companies. In these roles, she has leveraged her expertise in building and scaling financial operations and implementing ERP systems to support sales and transitions to public companies. Jessica has held senior financial roles in retail, distribution, and e-commerce at Agilux Laboratories, Charles River Laboratories, and Third Pole Therapeutics. She received her Master of Science in Accounting and Graduate Certificate in Taxation from Bentley University.

Vikki has more than fifteen years of combined synthetic and bioanalytical chemistry experience in the pharmaceutical and contract research industries. Prior to her most recent role as the Associate Director of Discovery Services at Charles River Laboratories, she held positions of increasing responsibility at AstraZeneca, Synta Pharmaceuticals, and Agilux Laboratories. Vikki has an exceptional track record for developing robust LC-MS/MS assays for quantitation of small molecule therapeutics and endogenous disease markers. Vikki received her BS/MS degrees in medicinal chemistry from Worcester Polytechnic Institute and completed her Ph.D. in organic chemistry at Boston College.

Danielle has extensive experience in the preclinical CRO industry. Her responsibilities have ranged from Study Director roles to Manager of In Vivo study teams. Prior to working at Charles River Laboratories on both East and West coasts, she worked at the University of Massachusetts Medical School. In each of Danielle’s roles, she has focused on process improvement, procedure refinement, and operational efficiency. Danielle is passionate about building partnerships with clients and providing exceptional customer service. She earned her BS in Biology from Framingham State University.

Sujoy is a seasoned expert in drug development with over 15 years of experience in both industry and academia. His career has spanned director level roles in immunoanalytical services at Charles River Laboratories, experimental biology at Envigo, and bioanalysis at Orum Therapeutics. Beginning as a Principal Scientist at Viracor-Eurofins, Sujoy focused on both ligand binding and cell-based assays for large molecule drug development. He excels in PK/PD assessments, biomarker assay development, and ensuring GLP compliance. Sujoy's expertise extends to drug discovery, toxicology, safety assessments, and clinical trial operations. He has managed GLP laboratories, led business development initiatives, and holds a Ph.D. in Microbiology and Immunology from the Chicago Medical School at Rosalind Franklin University of Medicine and Science, Illinois, USA.

Steve has held senior business development and operational roles at a variety of contract research laboratories, including Agilux Laboratories, where he was a Co-founder and Vice President of Sales and Marketing, Advion Bioservices, Charles River Laboratories, and Taylor Technology. In his advisory role, Steve brings a depth and breadth of directly relevant experiences to Meadowhawk Biolabs. Steve received his BS and MS degrees from the University of Manchester, U.K.

Peter is a life sciences investor and a serial entrepreneur. He currently serves as the Chairman of NanoImaging Services and Meadowhawk Biolabs–a role he has previously filled at multiple life science companies, including Agilux Laboratories, Magellan Diagnostics and Dynex Technologies. In addition, he has been a General Partner at Ampersand Capital Partners, CEO of Cohesive Technologies, and President of Primedica Corporation. Peter holds a BS in Economics from the Wharton School at the University of Pennsylvania and MS from MIT’s Sloan School of Management.

Herb is the Managing Partner of Ampersand Capital Partners, a healthcare-focused growth equity firm with over $2 billion under management. His current and past board seats include Agilux Laboratories, Avista, Brammer Bio, GENEWIZ, Genoptix, Nexelis, and Viracor-IBT Laboratories. He also serves on the College of Chemistry Advisory Board for the University of California, Berkeley. Herb holds a BS in Chemical Engineering from North Carolina State, and a Ph.D. in Chemistry from the University of California, Berkeley.